BASEL (dpa-AFX) - Swiss drug maker Novartis AG (NVS) reported that a wealth of new data from its respiratory portfolio would be presented at the European Respiratory Society or ERS International Congress, September 6-10, in Munich, Germany. Totally, 44 abstracts would be presented by Novartis, representing more than any other company at the congress.
Positive new results from the Phase III head-to-head LANTERN study demonstrated the superiority of once-daily, dual bronchodilator, Ultibro Breezhaler in improving lung function compared to twice-daily Seretide Accuhaler, in patients with moderate-to-severe COPD.
The QUANTIFY study's analyses showed that Ultibro Breezhaler significantly improved lung function and shortness of breath in patients with moderate-to-severe COPD, compared to the combination of tiotropium plus formoterol. In addition, results showed that Ultibro Breezhaler is comparable to tiotropium plus formoterol in improving health-related quality of life.
Copyright RTT News/dpa-AFX